> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approved Expanded Verzenio Use
- URL: https://www.fdaweb.com/fda-approved-expanded-verzenio-use/
- Published: 2018-02-26T12:00:00.000Z
- Updated: 2026-09-14T23:25:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140848

FDA has approved Eli Lilly’s Verzenio (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for treating postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. This is the third indication for Verzenio within five months; in9/2017, Verzenio became the first cyclin-dependent kinase 4 & 6 inhibitor approved in combination and as a single agent in metastatic breast cancer.

Expanded approval is based on the efficacy and safety demonstrated in the pivotal MONARCH 3 clinical trial. Data showed that Verzenio dosed orally at 150 mg twice daily on a continuous schedule with an AI demonstrated a greater than 28-month median progression-free survival in patients who received initial endocrine-based therapy for metastatic disease compared with 14.8 months for those on a placebo plus an AI.